Skip to main content
. 2017 Dec 4;6:163. doi: 10.1186/s40249-017-0377-0

Fig. 5.

Fig. 5

Patient HIV-1 RNA Load and CD4+ T Cell Count Receiving First Line Treatment Pre/Post Sanger Resistance Testing. a Patients (n = 157) at the time of Sanger DR testing with resistance to AZT. b AZT susceptible patients (n = 99) at the the time of Sanger DR testing. c Patients (n = 39) resistant to AZT by AfriPOLA. Means and statistically significant differences (ANOVA) are indicated